Episode Details: Our Guest: Sharon Rogers, CEO at AmyriAD Therapeutics What you’ll get out of this episode: Rogers’ background An overview of AmyriAD Therapeutics The company’s lead compound, AD101 Their clinical trials & what they’re showing Launching a Phase 3 Study What’s next? Watch and listen here: #345 – Sharon Rogers, CEO at AmyriAD Therapeutics…
April 18, 2023 A growing number of start-up companies are pursuing alternative strategies in drug development for patients with Alzheimer’s disease that bypass the beta amyloid hypothesis that has dominated the field for decades. Although the major manifestations of AD are global cognitive decline and loss of independent function, accessory symptoms include aberrant accumulation of…
Sharon L. Rogers CEO, AmyriAD Rogers brings the strength of 35 years of pharma experience to AmyriAD. She is best known as the worldwide leader of and development strategist b ehind the highly successful Alzheimer’s treatment donepezil (Aricept), which has been the standard of care for more than 25 years. Her first start-up was leading Eisai’s…
CFO Thought Leader Podast- From Tech to Biotech: Enjoying Today’s Journey | Galit Yaakobovitz, CFO, AmyriAD After Galit Yaakobovitz relocated from Israel to the United States back in the mid-2000s, there was little question that the move had given her career a boost. Still, it was the next relocation—the one that would move her and…
#36 Dr Sharon Rogers – Finding a cure for Alzheimer’s Disease with AmyriAD February 17, 2023 AmyriAD is an LA-based clinical-stage biotech company working to advance effective therapies for the treatment of Alzheimer’s Disease, bringing together decades of experience with the singular goal of easing the devastation it causes. The Company’s lead drug candidate, AD101,…
Talking about Alzheimer’s disease: current drugs, clinical trials, and the pipeline February 9, 2023 In this wide-ranging podcast, Sharon L. Rogers, CEO of the biotech AmyriAD Therapeutics, covers her career studying Alzheimer’s, how the disease works, what her company is working on, lecanemab, and the future of Alzheimer’s research and treatments. Listen to the podcast…
FDA Made the Right Call on Lilly’s Donanemab, Some Experts Say January 24, 2023 Thursday, the FDA rejected Eli Lilly’s Alzheimer’s disease candidate, donanemab, an investigational antibody to ameliorate the symptoms of Alzheimer’s disease (AD). While the news may have disappointed the company, some AD experts asserted the FDA’s actions were appropriate. What’s more, Lilly’s approach with donanemab is…
AmyriAD’s Alzheimer’s drug ready for Phase 3 trials January 11, 2023 AmyriAD CEO tempers expectations on lecanemab and explains how layering therapies may help “turn the clock back” further for Alzheimer’s patients. While much of the limelight at the recent Clinical Trials on Alzheimer’s Disease (CTAD) conference was focused on the data from Eisai and…
AmyriAD Therapeutics CEO Sharon L. Rogers shares the scoop on AmyriAD’s investigational Alzheimer’s drug AD101. December 12, 2022 The majority of experimental Alzheimer’s drugs are being designed to halt the progression of the disease — a strategy which so far has yielded a 99-percent failure rate. Trials for these drugs — mostly expensive antibody-infusion based therapies —…
Sharon Rogers of AMYRIAD Therapeutics Discusses the State of Treatments & Trials
